Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis

• Published in: Liver international Vol. 44; no. 5; pp. 1233 - 1242
• Main Authors: Lam, Laurent, Carrieri, Patrizia, Hejblum, Gilles, Bellet, Jonathan, Bourlière, Marc, Carrat, Fabrice
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-05-2024; Wiley-Blackwell
• Subjects: administrative claims; Antiviral agents; Antiviral Agents - therapeutic use; Antiviral drugs; chronic; Chronic infection; Data Analysis; Economic impact; Economics; Financial Stress; France; Global economy; healthcare; healthcare costs; Hepacivirus; Hepatitis; Hepatitis C; Hepatitis C - drug therapy; Hepatitis C, Chronic - drug therapy; Humans; Impact analysis; Infections; Insurance; Life Sciences; Patients; Resource utilization; Therapy; France; administrative claims; antiviral agents; chronic; hepatitis C; healthcare costs; healthcare
• ISSN: 1478-3223; 1478-3231; 1478-3231
• DOI: 10.1111/liv.15872

Background and Aims
The economic impact of managing patients with hepatitis C virus (HCV) infection remains unknown. This study aimed to assess the economic burden of chronic HCV infection from a national health insurance perspective and the impact of direct‐acting antivirals (DAAs) using nationwide real‐world data.
Methods
Patients with chronic HCV infection were identified from the French Health Insurance Claims Databases (SNDS) and matched for age and sex to the general population. Health resource utilization and reimbursements were summarized according to healthcare expenditure items from 2012 to 2021. The economic burden attributable to chronic HCV infection was evaluated over a 10‐year period. Finally, the impact of DAAs was estimated using economic data derived from the SNDS.
Results
A total of 145 187 patients with chronic HCV infection were identified. Among the patients eligible for DAA therapy, 81.5% had received DAA by the end of 2021. Over a 10‐year period, managing patients with chronic HCV infection resulted in an additional cost of €9.71 billion (95% confidence interval [CI]: €9.66–€9.78 billion) or €9191 (95% CI: €9134–€9252) per patient per year compared to the general population. After DAA therapy, patients with chronic HCV infection had a higher economic burden than the general population, with an additional cost of €5781 (95% CI: €5540–€6028) per patient at the fifth‐year post‐DAA therapy.
Conclusions
A significant economic burden persists among patients with HCV infection after DAA treatment. The high proportion of patients not treated with DAA therapy supports reinforcing policies for universal access.